GLP-1s’ Popularity Comes with Hidden Costs – And Opportunities – for Employers
The first GLP-1 drugs were approved for chronic weight management in 2014; however, it wasn’t until 2021, when Novo Nordisk got approval for semaglutide (Wegovy) (a stronger and more effective GLP-1) for weight management, that these drugs saw a meteoric rise in popularity. Even those for which weight loss is considered merely a “side effect”…